BioPharma Resources

Drug Trial Radar · NCT07947732

Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1

A Phase 2/3, Open-label, Single-Arm Study in the Pediatric Population With HIV-1 to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Long-Acting Regimen of Lenacapavir, Teropavimab, and Zinlirvimab Administered Twice Yearly

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion May 2032

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drugs lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) to assess how it is absorbed, modified, distributed and eliminated from the body of young people (the pharmacokinetics (PK) parameters of the drugs). It will also check the safety, and tolerability of LEN in combination with TAB, and ZAB in participants living with human immunodeficiency virus type 1 (HIV-1). The primary objectives of this study are to evaluate the PK parameters, safety, and tolerability of LEN, TAB, and ZAB.

Conditions

  • HIV-1-infection

Interventions

  • Lenacapavir TabletDrug

    Administered orally

  • Lenacapavir InjectionDrug

    Administered SC

  • TeropavimabDrug

    Administered IV

  • ZinlirvimabDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) parameters: Ctrough for LEN During the First Dosing Cycle (Day 1 to Week 26)Time frame: Day 1 to Week 26
  2. Pharmacokinetics (PK) parameters: Ctrough for TAB During the First Dosing Cycle (Day 1 to Week 26)Time frame: Day 1 to Week 26
  3. Pharmacokinetics (PK) parameters: Ctrough for ZAB During the First Dosing Cycle (Day 1 to Week 26)Time frame: Day 1 to Week 26
  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 26Time frame: First dose date up to Week 26
  5. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 26Time frame: First dose date up to Week 26

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jacobi Medical Center

    The Bronx, New York

  • AXCES Research Group, LLC

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.